Avidity Biosciences Announces Expected Record Date for Spin-Off
Stocks in this Quantisnow insightHealth Care
Historical context for RNA
Across the 3 sessions after earlier RNA headlines, the stock closed higher 3 times and lower 0 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RNA | SPY |
|---|---|---|---|
| Nov 19, 2025 | Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 | +0.1% | +0.4% |
| Nov 11, 2025 | Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | +1.2% | +0.2% |
| Oct 27, 2025 | Avidity Biosciences Enters into Agreement to be Acquired by Novartis AGand 1 other headline that session | +42.4% | +1.2% |
Quantisnow market dataNASDAQ
RNA
Atrium Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for RNA
Full RNA profile on Quantisnow Follow RNA and get a push notification the moment its next story breaks.